Skip to main content
Intended for healthcare professionals
Restricted access
Research article
First published online January 15, 2013

CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions

Abstract

CXCL13, a B-cell chemokine, has been proposed as a biomarker in a variety of conditions, some of which can mimic multiple sclerosis and can have very high levels. In this case-control study, cerebrospinal fluid (CSF) CXCL13 was elevated in multiple sclerosis, neuromyelitis optica and other inflammatory neurological controls compared with noninflammatory controls. Levels did not differentiate disease groups. For all subjects taken together, CSF CXCL13 correlated with CSF WBC, oligoclonal band numbers, CSF protein, EDSS, and neurofilament levels. In subgroup analyses, CSF CXCL13 correlated with CSF WBC in neuromyelitis optica and IgG index in multiple sclerosis. Additionally, serum CXCL13 was elevated in neuromyelitis optica.

Get full access to this article

View all access and purchase options for this article.

References

1. Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006; 129: 200–211.
2. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course. Mult Scler 2011; 17: 335–343.
3. Zhong X, Wang H, Dai Y, et al. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. J Neuroimmunol 2011; 240–241: 104–108.
4. Schmidt C, Plate A, Angele B, et al. A prospective study on the role of CXCL13 in Lyme neuroborreliosis. Neurology 2011; 76: 1051–1058.
5. Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO: A clinical CSF biomarker study. Neurology 2010; 75: 208–216.
6. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 2008; 358: 676–688.
7. Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial. Neurology 2010; 74: 1860–1867.
8. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443–1448.
9. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485–1489.
10. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre. Brain 2007; 130: 1235–1243.

Supplementary Material

File (5_alvareze_cxcl13_supplementary_figure_1.tif.gz)
File (5_alvareze_cxcl13_supplementary_figure_2.tif.gz)

Cite article

Cite article

Cite article

OR

Download to reference manager

If you have citation software installed, you can download article citation data to the citation manager of your choice

Share options

Share

Share this article

Share with email
EMAIL ARTICLE LINK
Share on social media

Share access to this article

Sharing links are not relevant where the article is open access and not available if you do not have a subscription.

For more information view the SAGE Journals article sharing page.

Information, rights and permissions

Information

Published In

Article first published online: January 15, 2013
Issue published: August 2013

Keywords

  1. Multiple sclerosis
  2. neuromyelitis optica
  3. CXCL13
  4. neuroinflammation
  5. neurofilament
  6. myelin basic protein
  7. biomarker

Rights and permissions

© The Author(s) 2013.
Request permissions for this article.

History

Manuscript received: August 14, 2012
Revision received: November 30, 2012
Manuscript accepted: December 7, 2012
Published online: January 15, 2013
Issue published: August 2013
PubMed: 23322500

Authors

Affiliations

Enrique Alvarez
Department of Neurology, Washington University in Saint Louis, USA
Laura Piccio
Department of Neurology, Washington University in Saint Louis, USA
Robert J Mikesell
Department of Neurology, Washington University in Saint Louis, USA
Eric C Klawiter
Department of Neurology, Washington University in Saint Louis, USA
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
Becky J Parks
Department of Neurology, Washington University in Saint Louis, USA
Robert T Naismith
Department of Neurology, Washington University in Saint Louis, USA
Anne H Cross
Department of Neurology, Washington University in Saint Louis, USA

Notes

Enrique Alvarez, Department of Neurology, Washington University in Saint Louis, Neurology Campus Box 8111, 660 S. Euclid Avenue, St Louis, MO 63110, USA. Email: [email protected]

Metrics and citations

Metrics

Journals metrics

This article was published in Multiple Sclerosis Journal.

VIEW ALL JOURNAL METRICS

Article usage*

Total views and downloads: 265

*Article usage tracking started in December 2016

Altmetric

See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores


Articles citing this one

Web of Science: 70 view articles Opens in new tab

Crossref: 69

  1. Intrathecal B cell-related markers for an optimized biological investi...
    Go to citation Crossref Google Scholar
  2. Cytokines/chemokines and immune checkpoint molecules in anti-leucine-r...
    Go to citation Crossref Google Scholar
  3. The Translatability of Multiple Sclerosis Animal Models for Biomarkers...
    Go to citation Crossref Google Scholar
  4. Asymptomatic sensitization to a cow’s milk protein induces sustained n...
    Go to citation Crossref Google Scholar
  5. Activated microglia promote invasion and barrier dysfunction of brain ...
    Go to citation Crossref Google Scholar
  6. The Brave New World of Early Treatment of Multiple Sclerosis: Using th...
    Go to citation Crossref Google Scholar
  7. A Scoping Review on Body Fluid Biomarkers for Prognosis and Disease Ac...
    Go to citation Crossref Google Scholar
  8. Downregulation of miR-125a-5p and miR-218-5p in Peripheral Blood Monon...
    Go to citation Crossref Google Scholar
  9. Update on Multiple Sclerosis Molecular Biomarkers to Monitor Treatment...
    Go to citation Crossref Google Scholar
  10. B Cells Specific CpG Induces High IL-10 and IL-6 Expression In Vitro i...
    Go to citation Crossref Google Scholar
  11. Detection of Neurofilament Light Chain with Label‐Free Electrolyte‐Gat...
    Go to citation Crossref Google Scholar
  12. Role of the CXCL13/CXCR5 Axis in Autoimmune Diseases
    Go to citation Crossref Google Scholar
  13. Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A ...
    Go to citation Crossref Google Scholar
  14. Are CSF CXCL13 concentrations solely dependent on intrathecal producti...
    Go to citation Crossref Google Scholar
  15. The blood biomarkers puzzle – A review of protein biomarkers in neurod...
    Go to citation Crossref Google Scholar
  16. A comprehensive review on the role of chemokines in the pathogenesis o...
    Go to citation Crossref Google Scholar
  17. Microglial Heterogeneity and Its Potential Role in Driving Phenotypic ...
    Go to citation Crossref Google Scholar
  18. Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
    Go to citation Crossref Google Scholar
  19. Immunology of Multiple Sclerosis
    Go to citation Crossref Google Scholar
  20. Chemokine CXCL13 acts via CXCR5-ERK signaling in hippocampus to induce...
    Go to citation Crossref Google Scholar
  21. CXCL13/CXCR5 signalling is pivotal to preserve motor neurons in amyotr...
    Go to citation Crossref Google Scholar
  22. Cerebrospinal Fluid Testing for Multiple Sclerosis
    Go to citation Crossref Google Scholar
  23. Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomar...
    Go to citation Crossref Google Scholar
  24. CXCL13 concentration in latent syphilis patients with treatment failur...
    Go to citation Crossref Google Scholar
  25. Immune Complex–Driven Generation of Human Macrophages with Anti-Inflam...
    Go to citation Crossref Google Scholar
  26. <p>Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis ...
    Go to citation Crossref Google Scholar
  27. Cerebrospinal Fluid and Blood Cytokines as Biomarkers for Multiple Scl...
    Go to citation Crossref Google Scholar
  28. Using biomarkers to predict clinical outcomes in multiple sclerosis
    Go to citation Crossref Google Scholar
  29. Bioinformatics Analyses Determined the Distinct CNS and Peripheral Sur...
    Go to citation Crossref Google Scholar
  30. A logical relationship for schizophrenia, bipolar, and major depressiv...
    Go to citation Crossref Google Scholar
  31. Clinical utility of a molecular signature in inflammatory demyelinatin...
    Go to citation Crossref Google Scholar
  32. Disease-Modifying Treatment in Progressive Multiple Sclerosis
    Go to citation Crossref Google Scholar
  33. Differentiation of remitting neuromyelitis optica spectrum disorders f...
    Go to citation Crossref Google Scholar
  34. Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Ne...
    Go to citation Crossref Google Scholar
  35. Significance of elevated Prohibitin 1 levels in Multiple Sclerosis pat...
    Go to citation Crossref Google Scholar
  36. Open-label, add-on trial of cetirizine for neuromyelitis optica
    Go to citation Crossref Google Scholar
  37. CXCL13 as a diagnostic marker of neuroborreliosis and other neuroinfla...
    Go to citation Crossref Google Scholar
  38. Multiple sclerosis, and other demyelinating and autoimmune inflammator...
    Go to citation Crossref Google Scholar
  39. Fluid biomarker and electrophysiological outcome measures for progress...
    Go to citation Crossref Google ScholarPub Med
  40. Case-control, exploratory study of cerebrospinal fluid chemokines/cyto...
    Go to citation Crossref Google Scholar
  41. Elevated C-X-C motif ligand 13 and B-cell-activating factor levels in ...
    Go to citation Crossref Google Scholar
  42. The cerebrospinal fluid in multiple sclerosis: far beyond the bands
    Go to citation Crossref Google Scholar
  43. Altered Expression of CXCL13 and CXCR5 in Intractable Temporal Lobe Ep...
    Go to citation Crossref Google Scholar
  44. Cerebrospinal Fluid Markers in Neuroinflammation: The Paradigm of Opti...
    Go to citation Crossref Google Scholar
  45. Blood-Brain Barrier Dysfunction during Central Nervous System Autoimmu...
    Go to citation Crossref Google Scholar
  46. Multiple Sclerosis
    Go to citation Crossref Google Scholar
  47. Chemokine CXCL13 expression was up-regulated in Clostridium difficile ...
    Go to citation Crossref Google Scholar
  48. Endogenous adaptation to low oxygen modulates T-cell regulatory pathwa...
    Go to citation Crossref Google Scholar
  49. Exosomal proteome analysis of cerebrospinal fluid detects biosignature...
    Go to citation Crossref Google Scholar
  50. Tertiary Lymphoid Organs in Central Nervous System Autoimmunity
    Go to citation Crossref Google Scholar
  51. BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at ...
    Go to citation Crossref Google Scholar
  52. Personalized therapy in multiple sclerosis: state of art and future pe...
    Go to citation Crossref Google Scholar
  53. Integration of metabolomics and proteomics in multiple sclerosis: From...
    Go to citation Crossref Google Scholar
  54. TGF-β induces the differentiation of human CXCL13-producing CD4 ...
    Go to citation Crossref Google Scholar
  55. CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disord...
    Go to citation Crossref Google Scholar
  56. Body fluid biomarkers for multiple sclerosis—the long road to clinical...
    Go to citation Crossref Google Scholar
  57. Predicting optimal response to B-cell depletion with rituximab in mult...
    Go to citation Crossref Google ScholarPub Med
  58. Genes involved in keratinization, keratinocyte and epithelium differen...
    Go to citation Crossref Google Scholar
  59. Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: A...
    Go to citation Crossref Google Scholar
  60. Biomarkers of Inflammation and Axonal Degeneration/Damage in Patients ...
    Go to citation Crossref Google Scholar
  61. Biomarkers for neuromyelitis optica
    Go to citation Crossref Google Scholar
  62. Body fluid biomarkers in multiple sclerosis: how far we have come and ...
    Go to citation Crossref Google Scholar
  63. Follicular Helper CD4 + T Cells in Human N...
    Go to citation Crossref Google Scholar
  64. Biomarkers of Therapeutic Response in Multiple Sclerosis: Current Stat...
    Go to citation Crossref Google Scholar
  65. Cerebrospinal fluid CXCL13 is a prognostic marker for aseptic meningit...
    Go to citation Crossref Google Scholar
  66. Stage-Specific Immune Dysregulation in Multiple Sclerosis
    Go to citation Crossref Google Scholar
  67. Cytokines and Chemokines in Neuromyelitis Optica: Pathogenetic and The...
    Go to citation Crossref Google Scholar
  68. Feasibility of the Use of Combinatorial Chemokine Arrays to Study Bloo...
    Go to citation Crossref Google Scholar
  69. Gene expression changes in aging retinal microglia: relationship to mi...
    Go to citation Crossref Google Scholar

Figures and tables

Figures & Media

Tables

View Options

Get access

Access options

If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:


Alternatively, view purchase options below:

Purchase 24 hour online access to view and download content.

Access journal content via a DeepDyve subscription or find out more about this option.

View options

PDF/ePub

View PDF/ePub

Full Text

View Full Text